Scientific deep-dive
When Pooling Studies Hides the Answer
A meta-analysis of 323,439 patients found no significant cardiovascular advantage for tirzepatide. The more important number sits beside it: the studies being pooled disagree with each other almost completely.
A meta-analysis of 323,439 patients asked whether tirzepatide prevents more cardiovascular events than the GLP-1 drugs it competes with. The answer was no significant difference (hazard ratio 0.85, with the interval crossing 1).[1] The more important number is buried beside it: I² = 90.4%, which means the studies being pooled disagree with each other almost completely.
What I² measures, and why 90% is a problem
When several studies of the same question produce different answers, some of that spread is ordinary sampling noise and some reflects real differences between the studies in their populations, definitions and confounding. I² estimates what proportion is the second kind.
A rough convention treats 25% as low, 50% as moderate and 75% as high. Ninety percent is off the end of that scale.
A pooled estimate from studies that disagree this much describes none of them.
The likely source is visible in the study list. Seven of the eight studies were observational, drawn from different health systems, with different patients, different comparison groups and different residual confounding. That those seven disagree is unsurprising. Pooling them does not resolve the disagreement; it conceals it.
The result, such as it is
| Outcome | Hazard ratio (95% CI) | Significant? |
|---|---|---|
| Major adverse cardiovascular events | 0.85 (0.70–1.04) | No |
| All-cause mortality | 0.90 (0.79–1.02) | No |
| Cardiovascular mortality | 0.88 (0.76–1.00) | No — the interval touches 1 |
All three point the same direction, which counts for something. None reaches significance. The third stops exactly on the boundary at 1.00, and someone will describe it as significant.
Exploratory subgroup analyses in people with type 2 diabetes did reach significance: all-cause mortality 0.85 (0.76–0.94) and heart failure 0.75 (0.58–0.97). Those are the numbers that will be quoted, and they are subgroups of an exploratory analysis inside a meta-analysis whose primary comparison was null and heterogeneous.
It agrees with the other evidence, which matters more than the pooling
Set the meta-analysis aside and look at what else exists. A claims-based study benchmarked its own method against two randomized trials, then compared tirzepatide with semaglutide on heart failure hospitalization or death in people with heart failure. It found 0.86 (0.70–1.06), a different outcome and a narrower comparison, but a null with almost the same numbers (covered in how to trust an observational study).
That completes a picture this register has been assembling. In the head-to-head, a randomized trial, tirzepatide beats semaglutide decisively on weight: 20.2% against 13.7%. On cardiovascular outcomes, no advantage has been demonstrated, and semaglutide is the agent with the mortality evidence across 262 trials.
None of that means tirzepatide is worse for the heart. It means the trial that would settle it has not reported, and the authors of this analysis say exactly that: further randomized trials are needed.
How to read the next meta-analysis you meet
- Find I² before the summary estimate. Above about 75%, the pooled number is describing a disagreement rather than a finding.
- Count how many included studies were randomized. One of eight, here.
- Check whether the significant results are subgroups. They usually are, and they usually get quoted.
- Prefer agreement between methods over precision within one. Two different approaches landing on the same answer is worth more than a tight interval around an average of contradictions.
Frequently Asked Questions
References
- 1.Silva JPMRJ, Nogueira BV, Sartori DL, et al. Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42410309.
Compare the sellers
Related research
A Benefit Nobody Observed
A cardiology journal reports GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease. Nobody in the study took the drug.
6 min read
The Biggest Number Is the Weakest
A prespecified SELECT analysis reports cardiovascular reductions of 26%, 21% and 34% across three definitions of liver fibrosis risk. The 34% is the only one that was not statistically significant.
7 min read
How to Trust an Observational Study
We have twice warned that a very large hazard ratio from an observational study is telling you about the study. This one, reporting 0.42 and 0.58, deserves trust, and the article names the specific techniques that earn it.
7 min read
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
The One Place People Felt Better
No obesity drug improved general quality of life across 43 trials. Both heart failure trials produced large symptom improvements. Those findings are not in conflict, because the heart failure trials used a disease-specific symptom measure.
8 min read
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →